Endpoint
exacerbations
THORACIC
The primary endpoint was the absolute reduction in the rate of severe exacerbations with mepolizumab 75 mg compared to placebo in the first 365 days of follow-up. In line with the American Thoracic Society (ATS) / European Respiratory Society (ERS) Task Force definition [